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Background
It is not uncommon for clinical trials to present results
on survival time as Kaplan-Meier survival curves that
cross, indicating non-proportional hazards. A recent
example was given in a pivotal trial in advanced non-
small cell lung cancer (The ‘IPASS study’ [1]). Trials
such as these present a hazard ratio and log-rank test
f o rt r e a t m e n tc o m p a r i s o na st h i si st h e i rp l a n n e dp r i -
mary analysis. However, the validity of such analysis is
questionable and has received published criticism. This
paper reviews the use of the log-rank test with crossing
curves and considers alternatives that have been
proposed.
Methods
The review of the alternative approaches includes
weighted log-rank tests (Wilcoxon, Tarone-Ware, Peto-
Prentice and Fleming-Harrington), supremum versions
of the log-rank test (modified Kolmogorov-Smirnov and
Renyi-type tests) which are based on the maximum dif-
ference between estimates of two survivor functions and
modified log-rank tests (Lin and Wang test using
squared differences at each time point, and Levene-type
test focusing on variance differences). In addition, meth-
ods based on splitting the analysis at the crossing point
have also been proposed. Methods are compared and
evaluated using both real and simulated datasets using
Weibull and Weibull-Cox distributions representing rea-
listic situations.
Results
Crossing survival curves is generally a result of the sur-
vival times having greater variance in one treatment
group than another. The performance of the log-rank
test and alternatives depend on the type of crossing
(early, mid or late) but in general the probability of a
Type II error is increased for log-rank and weighted
log-rank tests but performance is improved with the
alternatives. The choice of time-point for the split-analy-
sis is problematic. Standard software such as sts test
(Stata), proc lifetest (SAS) and survfit (R) and routines-
on-demand support some but not all the tests
considered.
Conclusions
There is a need in the clinical community to clarify
methods that are appropriate when survival curves
cross. Statistical analysis plans for clinical trials with sur-
vival as primary outcome measure should specify an
analysis dependent on the proportionality of hazard
rates and explicitly consider non-proportionality issues,
powering the analyses based on log-rank alternatives.
Modelling the survival data may be more appropriate
than simple univariate hypothesis tests when hazards
are not proportional. Finally, there are some feasibility
issues regarding software for such analysis that remain
to be tackled.
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